CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 1,118 enrolled
Drug / intervention
MEDI4736 (Durvalumab) +7 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02453282
NCT02453282Phase 3Active
CompareCT.gov

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)(MYSTIC).

AstraZeneca·interventional·Posted May 25, 2015·Updated May 12, 2026

In Brief

A Phase 3 clinical trial evaluating MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, and 6 other interventions for Non-Small-Cell Lung Carcinoma NSCLC. Active but no longer recruiting, targeting 1,118 participants across 196 sites in 17 countries.

Detailed Summary

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small-Cell Lung Carcinoma NSCLC
CountriesAustralia, Belgium, Canada, France, Germany, Hungary, Italy, Japan, Netherlands, Russia, South Korea, Spain, Switzerland, Taiwan, Thailand, United States, Vietnam
Collaborators--

Timeline

Phase 3Active
201620172018201920202021202220232024202520262027
First PostedMay 25, 2015
Enrollment StartJul 21, 2015
Primary CompletionOct 4, 2018
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 11.1 years ago

Interventions

MEDI4736 (Durvalumab)biological

MEDI4736 (Durvalumab)+Tremelimumabbiological

Paclitaxel + Carboplatindrug

Chemotherapy Agents

Gemcitabine + Cisplatindrug

Chemotherapy Agents

Gemcitabine + Carboplatindrug

Chemotherapy Agents

Pemetrexed + Cisplatindrug

Chemotherapy Agents

Pemetrexed + Carboplatindrug

Chemotherapy Agents

Tremelimumabbiological